Britain on Thursday launched a trial to assess the immune responses generated if doses of the COVID-19 vaccines from Pfizer Inc. and AstraZeneca Plc are combined in a two-shot schedule.
The British researchers behind the trial said data on vaccinating people with the two different types of coronavirus vaccines could help understanding of whether shots can be rolled out with greater flexibility around the world.
Initial data on immune responses is expected to be generated around June.
The trial will examine the immune responses of an initial dose of Pfizer vaccine followed by a booster of AstraZeneca's, as well as vice versa, with intervals of 4 and 12 weeks.
Matthew Snape, an Oxford vaccinologist who is leading the trial, said initial results could inform vaccine deployment in the second half of the year.
Both the mRNA shot developed by Pfizer and BioNTech and the adenovirus viral vector vaccine developed by Oxford University and AstraZeneca are currently being rolled out in Britain, with a 12-week gap between two doses of the same vaccine.
It is expected more vaccines will be added to the trial when they are approved and rolled out.
For more info, please go to https://globalnews.ca/news/7619191/covid-vaccine-dose-mixing-study/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#Coronavirus #COVID19 #Science #GlobalNews
The British researchers behind the trial said data on vaccinating people with the two different types of coronavirus vaccines could help understanding of whether shots can be rolled out with greater flexibility around the world.
Initial data on immune responses is expected to be generated around June.
The trial will examine the immune responses of an initial dose of Pfizer vaccine followed by a booster of AstraZeneca's, as well as vice versa, with intervals of 4 and 12 weeks.
Matthew Snape, an Oxford vaccinologist who is leading the trial, said initial results could inform vaccine deployment in the second half of the year.
Both the mRNA shot developed by Pfizer and BioNTech and the adenovirus viral vector vaccine developed by Oxford University and AstraZeneca are currently being rolled out in Britain, with a 12-week gap between two doses of the same vaccine.
It is expected more vaccines will be added to the trial when they are approved and rolled out.
For more info, please go to https://globalnews.ca/news/7619191/covid-vaccine-dose-mixing-study/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#Coronavirus #COVID19 #Science #GlobalNews
